A man types hair thinning treatments into a search bar and gets back a shelf: a foam, a serum, a shampoo, a laser comb, and a clinic offering peptide injections. Two of those items carry an FDA approval for regrowing hair. The rest carry marketing. The short answer, before the long one: minoxidil and finasteride are the only drugs the FDA has approved for common pattern hair loss, both approvals cover a narrower patch of scalp than the advertising suggests, and neither approved drug is a peptide.<\/p>\n
That last point matters more in 2026 than it did five years ago, because hair is now the front door to the peptide business. Clinics that opened for weight loss added hair protocols. Copper peptides moved from cosmetic jars into injection menus. The industry’s own search traffic says so: “peptide for hair growth” and “ghk-cu hair” both sit in the daily scanner our team runs on the peptide video market.<\/p>\n
So here is the map, drawn from the labels themselves rather than from the sales pages.<\/p>\n
The 5% minoxidil foam label that DailyMed published on September 29, 2026 is the most useful page in this market. Its stated use covers regrowth “on the top of the scalp (vertex only)”, and its do-not-use list names the case most men bring to a clinic: hair loss “on the front of the scalp”, because the product “is not intended for frontal baldness or receding hairline”.<\/p>\n
The same label sets the clock. Results may appear at two months with twice-daily use, and “for some men, you may need to use this product for at least 4 months before you see results”. Stop at four months with no regrowth and the label’s advice is to see a doctor, which is a more honest instruction than most clinic funnels offer.<\/p>\n
Two more lines deserve a spot above the fold on a product page. The first: “continued use is necessary to increase and keep your hair regrowth or hair loss will begin again”. The second: the label tells men with heart disease to ask a doctor first, and tells anyone with chest pain, a racing heartbeat, faintness, dizziness, sudden unexplained weight gain, or swollen hands and feet to stop and seek care.<\/p>\n
The fine print on the box is better patient education than the landing page. That is the standard to hold a clinic to.<\/p>\n
Prescription finasteride is the second approval, and its label is blunt about who it is for: male pattern hair loss “in MEN ONLY”, with efficacy in bitemporal recession not established, and not indicated for women. The Organon label, revised November 2023, describes three controlled trials in 1,879 men aged 18 to 41 with mild to moderate hair loss.<\/p>\n
The measured effect is a hair count inside a one-inch circle of scalp, compared with placebo. At 12 months the difference is 107 hairs. At five years it reaches 277 hairs, with hair count still above the starting line in the men who kept taking it, while the placebo group lost ground. Improvement peaks in the first two years and then slides slowly, which is the part of the graph that clinics tend to crop.<\/p>\n
Side effects in the 12-month trials look small in the label’s arithmetic: 1.4% of men on finasteride stopped because of a drug-related adverse experience, against 1.6% on placebo. A man who reads that number and assumes finasteride is risk-free has read half a sentence. The same label carries warnings about sexual side effects, depression, and a rare breast cancer signal in longer prostate studies of the same molecule at five times the dose. Prescribing it is a clinician’s job. Marketing it is not.<\/p>\n
Copper peptides are where the hair conversation meets the peptide business, so the evidence deserves to be stated precisely rather than repeated at second hand.<\/p>\n
The trial that gets quoted is in Annals of Dermatology, published in 2016 by Lee and colleagues at Kyungpook National University Hospital (PMID 27489425). It was randomized, double-blind, and six months long. Forty-five men aged 25 to 60 with pattern hair loss sprayed a synthesized complex of 5-aminolevulinic acid and the peptide GHK on the scalp once a night, at 100 mg\/ml, at 50 mg\/ml, or as a placebo.<\/p>\n
Hair count inside a one-centimeter circle rose by 52.6 hairs on the higher concentration and 71.5 on the lower one, against 9.6 on placebo, both differences statistically significant. Hair length showed no significant difference between the groups. Hair thickness showed no significant difference either. Patients rating their own result above “good” ran 26.7% on the higher concentration, 14.3% on the lower, and 7.1% on placebo. The authors reported no adverse events in any group.<\/p>\n
Now the limits, because they decide how to use that paragraph. Fifteen men per arm. One hospital. One specific synthetic complex, made under laboratory control, and not the shelf serum or the clinic vial wearing the same peptide name. One result that moved, alongside two that did not. A signal worth studying is not a treatment worth selling, and a directory that treats it as proven is selling something too.<\/p>\n
GHK-Cu and its cousin AHK-Cu sit in shampoos, scalp sprays and leave-in treatments sold as cosmetics. No cosmetic ingredient carries a therapeutic approval, and cosmetics cannot lawfully claim to treat hair loss.<\/p>\n
The FDA keeps a running page of warning letters about “drug claims made for products marketed as cosmetics,” and its own description of that page names hair restoration products among the targets. A product that promises regrowth has stepped over a line the FDA enforces. Read the claim and you have your answer about what the seller thinks the product does.<\/p>\n
Injectables are the sharper edge of this market, and the FDA has documented the pattern. In a warning letter dated December 10, 2024, the agency told Curtis Miller of Prime Vitality, doing business as Prime Peptides in Santa Barbara, that his site’s “Semaglutide” and “Retatrutide” products were unapproved new drugs sold in violation of the law.<\/p>\n
The sentence worth carrying into a hair consultation is this one: the FDA rejected the seller’s “research purposes only” and “not for human consumption” labels because the site’s own copy described what the products do inside a human body. That copy, in the agency’s reading, established the products as drugs for human use.<\/p>\n
Swap the peptide name and the logic holds. An injectable peptide with no approved drug behind it is an unapproved new drug, and a clinic invoice does not convert it into an approval. Compounding does not close the gap either: a compounded product is not an FDA-approved product, and the pharmacy that made it is not an approved manufacturer.<\/p>\n
Five questions, asked in writing, sort most clinics in about ten minutes.<\/p>\n
Our peptide clinic directory<\/a> lists providers state by state with those questions attached, and the peptide tracker<\/a> follows the regulatory status of the compounds regulators are actively reviewing.<\/p>\n For common pattern hair loss, the two drugs the FDA has approved are topical minoxidil and oral finasteride. Minoxidil’s label covers the top of the scalp and reports results from two to four months. Finasteride’s label reports a 107-hair advantage over placebo at 12 months and 277 hairs at five years in men aged 18 to 41. Neither approval covers all kinds of hair loss.<\/p>\n The 5% foam label says no. Its own do-not-use list includes hair loss on the front of the scalp, and states the product is not intended for frontal baldness or a receding hairline.<\/p>\n Minoxidil’s label allows two months for first results and at least four months for some men, with a doctor visit if nothing has changed by month four. Finasteride’s hair-count data was measured at 6 and 12 months, and the label describes improvement continuing into the second year.<\/p>\n The best human evidence is one six-month randomized trial of 45 men published in Annals of Dermatology in 2016, in which hair count rose significantly and hair length and thickness did not differ significantly from placebo. That trial tested a specific synthesized 5-ALA and GHK complex. Serums on shelves carry no approval and no obligation to match it.<\/p>\n An injectable is lawful when an approved drug backs it or when a licensed pharmacy compounds it for a patient under the rules that govern compounding. A peptide with neither behind it is an unapproved new drug, which is what the FDA told a peptide seller in December 2024 when it rejected the “research use only” label as a shield.<\/p>\n The label says it is not indicated for use in women, and warns that women who are pregnant or may become pregnant should not handle crushed or broken tablets because of absorption risk. Anyone told otherwise should ask that prescriber to show the label.<\/p>\n Two disclosures belong on the record. This page is a directory, not a clinic, and we do not sell peptides. The peptide figures quoted above come from one small randomized trial of a laboratory-synthesized complex, while the products sold to patients under similar names are not the products that trial tested. Nothing here is a dosing instruction or a substitute for a licensed clinician’s assessment.<\/p>\n Sources: DailyMed SPL, minoxidil 5% topical foam, published September 29, 2026<\/a>, DailyMed SPL, PROPECIA (finasteride) 1 mg, label revised November 2023<\/a>, Lee WJ et al., Annals of Dermatology, 2016, PMID 27489425<\/a>, FDA, warning letters addressing drug claims for products marketed as cosmetics<\/a>, FDA warning letter to Prime Vitality, December 10, 2024<\/a>.<\/p>\nFrequently asked questions<\/h2>\n
What is the most effective hair thinning treatment?<\/h3>\n
Does minoxidil work on a receding hairline?<\/h3>\n
How long does it take to know whether a treatment works?<\/h3>\n
Do copper peptide serums regrow hair?<\/h3>\n
Can a clinic sell peptide injections for hair loss?<\/h3>\n
Is finasteride safe for women?<\/h3>\n